• ,

Hepatitis B Virus Infection Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Hepatitis B Virus Infection Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Hepatitis B Virus Infection Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including Hepatitis B Virus Infection clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Hepatitis B Virus Infection pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hepatitis B Virus Infection NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from the Hepatitis B Virus Infection Pipeline Insight Report

  • DelveInsight’s Hepatitis B Virus Infection Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hepatitis B Virus Infection.
  • The leading Hepatitis B Virus Infection Companies such as Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences Dong-A ST Co. Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
  • Promising Hepatitis B Virus Infection Pipeline therapies such as EYP001a, VBR, AB-729, SOC NrtI, VIR-2218, NCO-48 Fumarate 4 mg, HB-AS02V, HBVAXPRO vaccine, ACH-126,443, Lamivudine, entecavir, FENDRIX, and others are under different phases of Hepatitis B Virus Infection clinical trials.
  • The Hepatitis B Virus Infection Companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis B Virus (HBV) Infection R&D. The Hepatitis B Virus Infection pipeline therapies under development are focused on novel approaches to treat/improve Hepatitis B Virus (HBV) Infection.

 

To explore more information on the latest breakthroughs in the Hepatitis B Virus Infection Pipeline treatment landscape of the report, click here @ Hepatitis B Virus Infection Pipeline Outlook

 

Hepatitis B Virus Infection Overview

Hepatitis means inflammation of the liver. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can all cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common hepatitis viruses are hepatitis A virus, hepatitis B virus, and hepatitis C virus. Hepatitis B is a liver infection caused by the hepatitis B virus. Some people with hepatitis B are sick for only a few weeks (known as “acute” infection), but for others, the disease progresses to a serious, lifelong illness known as chronic hepatitis B. Some people, especially those who get infected in adulthood, are able to clear the virus from their bodies without treatment. For other people, acute hepatitis B leads to life-long infection known as chronic hepatitis B. Over time, chronic hepatitis B can cause serious health problems, including liver damage, cirrhosis, liver cancer, and even death.

 

Recent Breakthroughs of Hepatitis B Virus Infection Treatment Landscape

  • AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.  AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase 2a randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.
  • ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.
  • VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

 

Request a sample and discover the recent advances in Hepatitis B Virus Infection Ongoing Clinical Trial Analysis and Medications, click here @ Hepatitis B Virus Infection Treatment Landscape

 

Hepatitis B Virus (HBV) Infection Emerging Drugs Profile

 

VIR 2218: Vir Biotechnology

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

 

ABI H3733: Assembly Biosciences

ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.

 

AB 729: Arbutus Biopharma

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.  AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase 2a randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.

 

Hepatitis B Virus Infection Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Hepatitis B Virus (HBV) Infection. The companies which have their Hepatitis B Virus (HBV) Infection drug candidates in the most advanced stage, i.e. phase II include, Arbutus Biopharma.

 

DelveInsight’s Hepatitis B Virus Infection Pipeline Report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Scope of the Hepatitis B Virus Infection Pipeline Report

  • Coverage- Global
  • Hepatitis B Virus Infection Companies- Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences Dong-A ST Co. Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
  • Hepatitis B Virus Infection Drugs- EYP001a, VBR, AB-729, SOC NrtI, VIR-2218, NCO-48 Fumarate 4 mg, HB-AS02V, HBVAXPRO vaccine, ACH-126,443, Lamivudine, entecavir, FENDRIX, and others.
  • Hepatitis B Virus Pipeline Segmentation: Phases, Product Type, Molecule Type, Route of Administration, Mechanism of Action 

 

Table of Content

  1. Introduction
  2. Hepatitis B Virus Infection Executive Summary
  3. Hepatitis B Virus Infection: Overview
  4. Hepatitis B Virus Infection Pipeline Therapeutics
  5. Hepatitis B Virus Infection Therapeutic Assessment
  6. Hepatitis B Virus (HBV) Infection– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase II)
  9. AB 729: Arbutus Biopharma
  10. Early Stage Products (Phase I)
  11. ABI H3733: Assembly Biosciences
  12. Preclinical and Discovery Stage Products
  13. Inactive Products
  14. Hepatitis B Virus Infection Key Companies
  15. Hepatitis B Virus Infection Key Products
  16. Hepatitis B Virus Infection – Unmet Needs
  17. Hepatitis B Virus Infection – Market Drivers and Barriers
  18. Hepatitis B Virus Infection – Future Perspectives and Conclusion
  19. Hepatitis B Virus Infection Analyst Views
  20. Hepatitis B Virus Infection Key Companies
  21. Appendix

 

Got Queries? Find out the related information on Hepatitis B Virus Infection Mergers and acquisitions, Hemophilia Licensing Activities @ Hepatitis B Virus Infection Emerging Drugs, and Recent Trends

 

Related Report– Interbody Cages Market | Acoustic Neuroma Market

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-market